GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
暂无分享,去创建一个
P. Pedrazzoli | F. Locatelli | R. Schiavo | S. Siena | D. Montagna | R. Maccario | C. Perotti | I. Turin | E. Montini | E. Carretto | C. Tullio | M. La Grotteria
[1] Wang-gang Zhang,et al. Strategies of antigen-specific T-cell-based immunotherapy for cancer. , 2005, Cancer biotherapy & radiopharmaceuticals.
[2] T. Waldmann,et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[3] S. Rosenberg,et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Offringa. Tumour immunology exploitation of the weapon of immune destruction for cancer therapy: taking aim before firing. , 2005, Current opinion in immunology.
[5] F. Locatelli,et al. T lymphocytes of recipient origin may contribute to the recovery of specific immune response toward viruses and fungi in children undergoing cord blood transplantation. , 2004, Blood.
[6] P. Pedrazzoli,et al. Ex vivo generation and expansion of anti‐tumor cytotoxic T‐cell lines derived from patients or their HLA‐identical sibling , 2004, International journal of cancer.
[7] Antonio Lanzavecchia,et al. Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.
[8] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] F. Sallusto,et al. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. , 2003, Blood.
[10] S. Larson,et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.
[11] Rustom Antia,et al. Lineage relationship and protective immunity of memory CD8 T cell subsets , 2003, Nature Immunology.
[12] J. Thompson,et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[13] M. Raffeld,et al. Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.
[14] S. Endres,et al. Apoptotic Pancreatic Tumor Cells Are Superior to Cell Lysates in Promoting Cross-Priming of Cytotoxic T Cells and Activate NK and γδ T Cells , 2002 .
[15] A. Vitiello,et al. Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. , 2001, Blood.
[16] S. Rosenberg. Progress in the development of immunotherapy for the treatment of patients with cancer , 2001, Journal of internal medicine.
[17] A. Mackensen,et al. Induction and clonal expansion of tumor‐specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells , 2001, International journal of cancer.
[18] S. H. van der Burg,et al. Strategies for immunotherapy of cancer. , 2000, Advances in immunology.
[19] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.
[20] M. Croce,et al. Assessment of methods for primary tissue culture of human breast epithelia. , 1998, Journal of experimental & clinical cancer research : CR.
[21] R. Freshney. Induction of differentiation in neoplastic cells. , 1985, Anticancer research.